Cód QR

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma

PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB). PD-L1 promoter methylation is an epigenetic mechanism that has been shown to regulate PD-L1 mRNA expression in vari...

Cur síos iomlán

Sábháilte in:
Príomhchruthaitheoirí: Niklas Klümper, Lennert Wüst, Jonas Saal, Damian J. Ralser, Romina Zarbl, Jonas Jarczyk, Johannes Breyer, Danijel Sikic, Bernd Wullich, Christian Bolenz, Florian Roghmann, Michael Hölzel, Manuel Ritter, Sebastian Strieth, Arndt Hartmann, Philipp Erben, Ralph M. Wirtz, Jennifer Landsberg, Dimo Dietrich, Markus Eckstein
Formáid: Artigo
Teanga:Inglês
Foilsithe / Cruthaithe: Taylor & Francis Group 2023-12-01
Sraith:OncoImmunology
Ábhair:
biomarker
bladder cancer
CD274
DNA methylation
immune checkpoint blockade
immunotherapy
Rochtain ar líne:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2267744
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla